

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

March 11, 2025

Consolidated Financial Results for the Three Months Ended January 31, 2025 (Under Japanese GAAP)



Company name: CellSource Co., Ltd.
 Listing: Tokyo Stock Exchange
 Securities code: 4880
 URL: <https://www.cellsource.co.jp/>
 Representative: Takashi Sawada, Representative Director and CEO
 Inquiries: Tomohiro Iga, Executive Officer and General Manager of Corporate Division
 Telephone: +81-3-6455-5308
 Scheduled date to commence dividend payments: —
 Preparation of supplementary material on financial results: Yes
 Holding of financial results briefing: Yes (for investors and analysts)

(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated Financial Results for the Three Months Ended January 31, 2025 (from November 1, 2024 to January 31, 2025)

(1) Consolidated operating results (cumulative)

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Three months ended January 31, 2025	849	—	(62)	—	(60)	—	(45)	—
January 31, 2024	—	—	—	—	—	—	—	—

Note: Comprehensive income: Three months ended January 31, 2025: ¥(45) million [—%]
 Three months ended January 31, 2024: ¥— million [—%]

	Basic earnings per share	Diluted earnings per share
	Yen	Yen
Three months ended January 31, 2025	(2.30)	—
January 31, 2024	—	—

Notes: 1. The Company has prepared quarterly consolidated financial statements from the first quarter of the fiscal year ending October 31, 2025. Therefore, figures for the three months ended January 31, 2024 and year-on-year changes as well as year-on-year changes for the three months ended January 31, 2025 are not stated.

2. Diluted earnings per share for the three months ended January 31, 2025 are not stated because, although potential shares exist, basic loss per share was recorded.

(2) Consolidated financial position

	Total assets	Net assets	Equity-to-asset ratio
	Millions of yen	Millions of yen	%
As of January 31, 2025	6,882	5,893	85.0
October 31, 2024	—	—	—

Reference: Equity

As of January 31, 2025: ¥5,850 million

As of October 31, 2024: ¥— million

Note: The Company has prepared quarterly consolidated financial statements from the first quarter of the fiscal year ending October 31, 2025. Therefore, figures as of October 31, 2024 are not stated.

2. Cash Dividends

	Annual dividends per share				
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended October 31, 2024	—	0.00	—	5.00	5.00
Fiscal year ending October 31, 2025	—				
Fiscal year ending October 31, 2025 (Forecast)		0.00	—	5.00	5.00

Note: Revisions to the forecast of cash dividends most recently announced: None

3. Consolidated Financial Result Forecasts for the Fiscal Year Ending October 31, 2025 (from November 1, 2024 to October 31, 2025)

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Basic earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Full year	4,501	—	370	—	372	—	255	—	12.88

Notes: 1. Revisions to the financial result forecast most recently announced: None

2. The Company has shifted to consolidated accounting from the first quarter of the fiscal year ending October 31, 2025. Therefore, year-on-year changes are not stated.

* **Notes**

(1) Significant changes in the scope of consolidation during the period: Yes

Newly included: 1 company (Hybrid Medical Co., Ltd.)

Excluded: —

(2) Adoption of accounting treatment specific to the preparation of quarterly consolidated financial statements: None

(3) Changes in accounting policies, changes in accounting estimates, and restatement

(i) Changes in accounting policies due to revisions to accounting standards and other regulations: None

(ii) Changes in accounting policies due to reasons other than (i): None

(iii) Changes in accounting estimates: None

(iv) Restatement: None

(4) Number of issued shares (common shares)

(i) Total number of issued shares at the end of the period (including treasury shares)

As of January 31, 2025	19,812,762 shares
As of October 31, 2024	19,806,100 shares

(ii) Number of treasury shares at the end of the period

As of January 31, 2025	580 shares
As of October 31, 2024	580 shares

(iii) Average number of shares outstanding during the period (cumulative from the beginning of the fiscal year)

Three months ended January 31, 2025	19,809,108 shares
Three months ended January 31, 2024	19,791,535 shares

* Review of the Japanese-language originals of the attached quarterly consolidated financial statements by certified public accountants or an audit firm: None

* Proper use of earnings forecasts and other special matters

The earnings forecasts and forward-looking statements described herein are based on information currently available to the Company and certain assumptions deemed reasonable, and are not intended to be a promise by the Company to achieve them. As such, actual results may differ significantly from these forecasts due to a wide range of factors.

(Method of obtaining the supplementary material on financial results and details of the financial results briefing)
The Company plans to hold a briefing online for investors and analysts on Tuesday, March 11, 2025.

2. Quarterly Consolidated Financial Statements and Principal Notes

(1) Quarterly Consolidated Balance Sheets

(Thousands of yen)

As of January 31, 2025

Assets	
Current assets	
Cash and deposits	4,264,049
Accounts receivable - trade	274,282
Merchandise and finished goods	91,400
Work in process	52,440
Raw materials and supplies	135,081
Other	93,001
Allowance for doubtful accounts	(5,102)
Total current assets	4,905,152
Non-current assets	
Property, plant and equipment	
Buildings, net	742,500
Other, net	342,422
Total property, plant and equipment	1,084,923
Intangible assets	56,622
Investments and other assets	
Other	836,290
Allowance for doubtful accounts	(165)
Total investments and other assets	836,125
Total non-current assets	1,977,671
Total assets	6,882,824

(Thousands of yen)

As of January 31, 2025

Liabilities	
Current liabilities	
Accounts payable - trade	63,148
Income taxes payable	7,963
Provision for bonuses	33,910
Provision for bonuses for directors (and other officers)	3,754
Provision for loss on orders received	2,657
Provision for share-based payments	10,501
Provision for loss on contract	34,166
Other	250,003
Total current liabilities	406,105
Non-current liabilities	
Asset retirement obligations	295,851
Provision for loss on contract	233,849
Other	53,085
Total non-current liabilities	582,786
Total liabilities	988,892
Net assets	
Shareholders' equity	
Share capital	1,428,074
Capital surplus	1,338,074
Retained earnings	3,075,557
Treasury shares	(1,703)
Total shareholders' equity	5,840,004
Accumulated other comprehensive income	
Valuation difference on available-for-sale securities	10,353
Total accumulated other comprehensive income	10,353
Share acquisition rights	43,574
Total net assets	5,893,931
Total liabilities and net assets	6,882,824

(2) Quarterly Consolidated Statements of Income and Comprehensive Income

Quarterly Consolidated Statements of Income

Three Months Ended January 31

(Thousands of yen)

	For the three months ended January 31, 2025
Net sales	849,186
Cost of sales	383,339
Gross profit	465,847
Selling, general and administrative expenses	528,014
Operating loss	(62,167)
Non-operating income	
Gain on sale of non-current assets	1,678
Refund of defined contribution pension plan	1,230
Miscellaneous income	773
Other	63
Total non-operating income	3,744
Non-operating expenses	
Interest expenses	291
Loss on sale of non-current assets	830
Organization expenses	963
Other	3
Total non-operating expenses	2,088
Ordinary loss	(60,510)
Extraordinary income	
Gain on reversal of share acquisition rights	3,134
Total extraordinary income	3,134
Loss before income taxes	(57,376)
Income taxes - current	882
Income taxes - deferred	(12,794)
Total income taxes	(11,911)
Loss	(45,464)
Loss attributable to owners of parent	(45,464)

Quarterly Consolidated Statements of Comprehensive Income

Three Months Ended January 31

(Thousands of yen)

	For the three months ended January 31, 2025
Loss	(45,464)
Comprehensive income	(45,464)
Comprehensive income attributable to	
Comprehensive income attributable to owners of parent	(45,464)